The U.S. continues to charge significantly higher prices for prescription drugs compared to similarly wealthy countries.
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.
The stock's fall snapped a two-day winning streak.
Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) ...
Dr. Robert A. Winn discusses efforts to increase diversity in clinical trials on an episode of Radio Health Journal.
Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
In 2023, drug companies launched new medications at prices 35 percent higher than the year before. On January 1, Pfizer ...
Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...
This was the stock's second consecutive day of gains.
Bullish option flow detected in Bristol Myers ( BMY) Squibb with 203,938 calls trading, 22x expected, and implied vol increasing over 5 points to 22.90%. Jan-25 52.5 calls and Jan-25 50 calls are the ...